Scarica l'app Stockscreener
0.00
100.00%
-1.71
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Comparing Sana Biotechnology (NASDAQ:SANA) & Aptose Biosciences (NASDAQ:APTO) - Defense World
Learn to Evaluate (APS) using the Charts (APS:CA) - news.stocktradersdaily.com
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
(APS) Investment Strategy and Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Announces Auditor Not Standing for Re-Appointment - The Manila Times
Major Red Flag: KPMG Abandons Aptose Over Complex Financial Instrument Controls - Stock Titan
Aptose Biosciences to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference - Nasdaq
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Aptose Biosciences announces change in accounting firm By Investing.com - Investing.com India
Aptose Biosciences announces change in accounting firm - Investing.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com - Defense World
(APS) Daily Stock Insights (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average – What’s Next? - The AM Reporter
Objective long/short (APS) Report (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
(APS) Technical Data (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences shares to delist from Nasdaq as of April 2 - Yahoo Finance
APTO stock touches 52-week low at $1.86 amid sharp annual decline - Investing.com Australia
APTO stock touches 52-week low at $1.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Stock Market Shakes As Major Firms See Sharp Declines - Finimize
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):